LivaNova PLC
Financials
Valuation Metrics
LivaNova PLC's Market Cap is $4.29B. At end of 2025 it was $3.35B. Ranked #1473 of 3,121 in US market (top 47%), #510 of 1,463 on NASDAQ (top 35%), #92 of 205 in Health Care Equipment & Services (top 45%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $4.29B | US#1,473/3,121 Sec#92/205 |
| Revenue | $1.47B | US#1,643/3,121 Sec#100/205 |
| Net Income | $189M | US#1,316/3,121 Sec#63/205 |
| Total Assets | $2.64B | US#1,900/3,121 Sec#93/205 |
| Net Assets | $1.33B | US#1,573/3,121 Sec#84/205 |
| Employees | 3,300 | US#1,433/3,121 Sec#101/205 |
| Value | ||
| P/E | 22.72x | US#1,296/3,121 Sec#37/205 |
| P/B | 3.23x | US#1,834/3,121 Sec#100/205 |
| P/S | 2.91x | US#1,670/3,121 Sec#114/205 |
| EV/EBITDA | 22.80x | US#2,014/3,121 Sec#95/205 |
| FCF Yield | 3.46% | US#1,735/3,121 Sec#95/205 |
| Profitability | ||
| ROE | 14.23% | US#948/3,121 Sec#45/205 |
| ROA | 7.14% | US#767/3,121 Sec#47/205 |
| Op. Margin | 13.48% | US#1,319/3,121 Sec#48/205 |
| Revenue Growth | 12.39% | US#1,083/3,121 Sec#73/205 |
| Financial Health | ||
| Debt Ratio | 99.26% | US#1,099/3,121 Sec#104/205 |
| Total Debt | $352M | US#2,047/3,121 Sec#109/205 |
| FCF | $148M | US#1,556/3,121 Sec#90/205 |
| Cash | $517M | US#1,056/3,121 Sec#59/205 |
| Current Ratio | 1.45x | US#1,722/3,121 Sec#152/205 |
| Net Debt/EBITDA | -0.91x | US#297/3,121 Sec#24/205 |
| Performance | ||
| 1Y Return | 39.53% | US#675/3,121 Sec#58/205 |
| 1M Return | -3.50% | US#1,318/3,121 Sec#115/205 |
| From 52W High | -9.04% | US#649/3,121 Sec#62/205 |
| 1Y MDD | -18.89% | US#625/3,121 Sec#13/205 |
| Trading | ||
| Volume | 511,293 shares | US#1,903/3,121 Sec#130/205 |
| Trading Value | $40M | US#1,338/3,121 Sec#96/205 |
| Per Share | ||
| EPS | $3.43 | US#969/3,121 Sec#52/205 |
| BPS | $24.13 | US#1,079/3,121 Sec#64/205 |
Company Info
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and difficult-to-treat depression. This segment also includes the development and clinical testing of LivaNova's aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, and other healthcare professionals, hospitals, and other medical institutions and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.